Proprietary ADC Pipeline

About Araris Biotech

Araris Biotech is developing a disruptive ADC linker technology designed to overcome key limitations of current ADC platforms, including heterogeneity, instability, and complex manufacturing. Its proprietary peptide linker attaches payloads site-specifically to a specific amino acid (Q295) in the antibody's Fc region, preserving antibody function and improving pharmacokinetics. The company has secured significant venture funding and established key partnerships with Taiho Oncology and Chugai Pharmaceutical, positioning it to advance its internal pipeline and out-license its platform technology.

About SYNDIVIA

Syndivia is a private, preclinical-stage biotech developing next-generation antibody-drug conjugates (ADCs) through its proprietary GeminiMab platform. The platform's key differentiator is its ability to perform site-specific conjugation at the native antibody hinge region without requiring enzyme engineering or sequence modification, enabling optimal DARs (1, 2, 4) and preserving antibody integrity. This approach is designed to create ADCs with enhanced therapeutic windows through improved tumor penetration and safety profiles. The company is building a proprietary pipeline of ADC candidates while actively protecting its technology through an extensive patent strategy.

Therapeutic Areas

Other Oncology (unspecified) Drugs